A Patient with Angiosarcoma of the Scalp in whom the Tumor Shrank During the Administration of Pazopanib

Abstract

A 69-year-old man with head angiosarcoma started receiving electron beam radiation therapy and intravenous IL-2therapy. After completion of electron beam radiation therapy, he received weekly paclitaxel therapy. As numbness of the limbs exacerbated, the administration interval of paclitaxel was extended. However, purpura of the scalp and right posterior ear, and cervical lymph node metastases were detected. Paclitaxel was discontinued and pazopanib administration was started,but adverse reactions, such as hypertension, thrombopenia, and increases in the levels of liver enzymes, were observed in the early phase. Administration was discontinued 26 days after its start. CT 25 days after the start of pazopanib administration revealed a reduction in the right cervical lymph node. However, bilateral hemopneumothorax developed 2months after the discontinuation of administration, and pneumonia simultaneously developed, leading to death. In the present case,pazopanib was effective, although the administration period was limited. Skin Research, 18 : 79-84, 2019